Alfasigma announces positive results from OLINGUITO phase 3 trial of filgotinib to treat adult patients with active ...
Alfasigma S.p.A announced positive topline results from the OLINGUITO phase 3 clinical trial (NCT05785611; Eudra CT 2022-501354-10-01), evaluating filgotinib (marketed as Jyseleca in approved indications) to treat adult patients with active axial …